YBX1 and neoplasm: MiR-216a acts as an tumor suppressor in SCLC by targeting and downregulating the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) (Wang et al., 2018), although it is likely that these effects are also, in part, due to YBX1 downregulation.